Barclays analyst Eddie Kim lowered the firm’s price target on Innovex (INVX) to $13 from $16 and keeps an Underweight rating on the shares. The company reported a solid Q1 and guided Q1 EBITDA in line, the analyst tells investors in a research note. Despite no guidance for the second half of 2025, the firm expects Innovex’s financials to decline in the back half of the year.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVX: